Rise in incidence of diabetes across the globe has elevated the need of innovative diabetic management devices which in turn has increased adoption of continuous glucose monitoring (CGM) devices. The existing glucose monitoring devices have few gaps which are bridged by the innovative CGM. With continuous glucose monitoring, significant improvement has been observed in stabilizing elevated A1C levels which in turn reduces risk of developing long term diabetic complications. Other driving factors for CGM market are technological innovation in the form of artificial pancreas, increasing awareness among developed, developing and under developed economies, and rise in incidences of diabetic patients. Research Beam Model: Research Beam Product ID: 88 5370 USD New
Continuous Glucose Monitoring Market, Continuous Glucose Monitoring Market Report, Continuous Glucose Monitoring Market Reports, Continuous Glucose Monitoring Market Research - Research Beam
 
 

Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 - 2020

  • Category : Medical Devices
  • Published On : December   2013
  • Pages : 92
  • Publisher : Allied Market Research
 
 
 

Demand for innovative diabetic management devices worldwide has increased the adoption of CGM- Continuous Glucose Monitoring Devices. Major reason for rising popularity of CGMs is its efficiencies to stabilize the raised levels of A1C, which reduces the possibilities of a long term diabetic problem. Other factors that drive the growth of CGM market are innovative technologies such as artificial pancreas, rising awareness in developed, under developed and developing nations, and rise in cases of diabetics. However, lack of reimbursements policies for CGM, stringent government regulations, lack of accuracy and higher costs are restricting the growth of market.

In the year 2012, global continuous glucose monitors market stood at $194.8 million. The report forecasts the market to reach $568.5 million by 2020, registering a CAGR of 14.8% during 2013-2020.

SEGMENT ANALYSIS

In the product segment analysis, insulin pump market would witness fastest growth followed by glucose sensors market. Factor that drives the growth of insulin pump market is insulin integration with CGMs, which is an important step to close the loop algorithm. Further, the need to replace glucose sensors after every 4 to 7 days, glucose sensors market would generate maximum revenues during the projected period.

In terms of application market, Global CGM market consist of Diagnostics, Hospitals and Home settings. Home setting segment,, would be the maximum revenue generators by 2020.

North America is the leading geographical region in terms of revenue due to earlier adoption of advanced technology, higher adoption, reimbursements and rising patient pool. However, Asia Pacific would be the fasted growing geographical region owing to its rising patient pool, rise in incomes, and increasing penetration of key firms and rising standard of livings.

Top companies in the CGM market are Medtronics, Animas Corporation,Dexcom,Ypsomed AG, Miraculins, Inc and Omnipodcomprising others. Key strategies implemented by the market players are Collaborations, approvals and Product launches.

KEY BENEFITS OF THE REPORT

  • The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self-monitoring glucose devices, approval for artificial pancreas and many more
  • Market is forecast for 2013 -2020, with market revenues for 2 historic years of 2010 and 2012
  • Identification and analysis of of nvestment pockets for CGM manufacturers
  • Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market
  • Analysis of regulatory framework that controls the newly lauched CGM devices and provides you with detailed information on reimbursement policies
  • The report identifies and profiles key market participants who would drive innovation in the CGM market

CHAPTER 1 INTRODUCTION

1.1 Objectives and Scope
1.2 Report Description
1.3 Key Benefits of the Report
1.4 Research Methodology

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 GLOBAL CONTINUOUS GLUCOSE MONITORS MARKET OVERVIEW

3.1 Healthcare Expenditure on Diabetes Worldwide
3.2 Type-1 Diabetics to Remain Key Target for CGM Market

3.2.1 Type-1 Diabetes

3.2.1.1 Type-1 Diabetes in Young People

3.2.2 Type-2 Diabetes

3.2.2.1 Type-2 Diabetes in Young People

3.2.3 Gestational Diabetes
3.2.4 Other Types of Diabetes

3.3 Market Intelligence

3.3.1 Top Factors Impacting Continuous Glucose Monitors Market, 2013-2020

3.3.1.1 Fda Approval of Artificial Pancreas
3.3.1.2 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.3.1.3 Rise in Incidences of Diabetes Cases Globally
3.3.1.4 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.3.1.5 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.3.1.6 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM
3.3.1.7 Strict Regulatory Impositions
3.3.1.8 Increase in Awareness Among Developing and Underdeveloped Economies

3.3.2 Top Three Winning Strategies in the Continuous Glucose Monitors Market
3.3.2.1 Global Market Players Positioning
3.3.3 Top Investment Pockets in Continuous Glucose Monitors Market

3.3.3.1 Continuous Glucose Monitors Market – by Device
3.3.3.2 Continuous Glucose Monitors Market – by Applications
3.3.3.3 Continuous Glucose Monitors Market – by Geography

3.4 Regulations
3.5 Reimbursement Scenario
3.6 Market Dynamics

3.6.1 Drivers

3.6.1.1 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.6.1.2 FDA Approval of Artificial Pancreas Enables Closing the Loop and Overcomes the Limitation of Current Diabetes Care Management System
3.6.1.3 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.6.1.4 Rise in Incidences of Diabetes Cases Globally
3.6.1.5 Increase in Awareness Among the Population in Developing and Underdeveloped Economies

3.6.2 Restraints

3.6.2.1 Strict Regulatory Impositions
3.6.2.2 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.6.2.3 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM

3.6.3 Market Opportunity

3.6.3.1 Growth in Emerging Market

3.6.4 Winning Strategies for Mncs in Emerging Markets

3.6.4.1 Tailoring the Existing Products to the Local Market Needs
3.6.4.2 Adoption of a Proactive Hybrid Model Rather Than Distributor Management
3.6.4.3 Service Rendered Makes a Difference
3.6.4.4 Partnership and Acquisition Key to Enhance Reach and Market Position
3.6.4.5  Adopting An Emerging-Market Attitude

CHAPTER 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY DEVICES

4.1 Transmitter and Receivers
4.2 Sensors

4.2.1 Market Trend

4.2.1.1 Non-Invasive Glucose Sensors
4.2.1.2 Subcutaneous Sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional Technology – Holter-Type Retrospective Sensors
4.2.1.4 Advanced Technology – Real-Time Sensors

4.3 Insulin Pump

4.3.1 Advantages of Insulin Pump
4.3.2 Disadvantages of Insulin Pump
4.3.3 Market Trend

CHAPTER 5 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET - BY APPLICATION

5.1 Diagnostics/Clinics
5.2 Hospitals
5.3 Home Settings
5.4 Role of CGM in Private Practice

5.4.1 Team Members
5.4.2 Clinical Space
5.4.3 Scheduling
5.4.4 Keeping the Patients Informed

CHAPTER 6 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET – BY AGE

6.1 Children and Teens
6.2 Youth
6.3 Middle Elderly and Aged

CHAPTER 7 CGM SYSTEMS MARKET BY GEOGRAPHY

7.1 North America
7.2 Europe
7.2.1 Financial Cost Incurred
7.3 Asia Pacific
7.4 Row

CHAPTER 8 COMPANY PROFILES

8.1 Medtronic Inc.

8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Business Performance
8.1.4 Strategic Moves and Developments

8.1.4.1 Principal Strategies: Product Launch
8.1.4.2 Secondary Strategies: Approval
8.1.4.3 Other Strategies: Collaboration

8.1.5 SWOT Analysis & Strategic Conclusions

8.2 Dexcom Inc.

8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Business Performance
8.2.4 Strategic Moves and Developments

8.2.4.1 Principal Strategies: Agreement/Partnership
8.2.4.2 Secondary Strategies: Acquisition

8.2.5 SWOT Analysis & Strategic Conclusions

8.3 Novo Nordisk

8.3.1 Company Profile
8.3.2 Company Snapshot
8.3.3 Strategic Moves and Developments
8.3.4 SWOT Analysis & Strategic Conclusions

8.4 Spring Health Solution Ltd

8.4.1 Company Profile
8.4.2 Company Snapshot
8.4.3 Strategic Moves and Developments

8.4.3.1 Principal Strategies

8.4.4 SWOT Analysis & Strategic Conclusions

8.5 Roche

8.5.1 Company Profile
8.5.2 Company Snapshot
8.5.3 Strategic Moves and Developments
8.5.4 SWOT Analysis & Strategic Conclusions

8.6 Animas Corporation

8.6.1 Company Profile
8.6.2 Company Snapshot
8.6.3 Strategic Moves and Developments

8.6.3.1 Principal Strategies

8.6.4 SWOT Analysis & Strategic Conclusions

8.7 Ypsomed AG

8.7.1 Company Profile
8.7.2 Company Snapshot
8.7.3 Strategic Moves and Developments

8.7.3.1 Principal Strategies: Product Expansion
8.7.3.2 Secondary Strategies: New Subsidiary
8.7.3.3 Other Strategies: Acquisition and Agreements

8.7.4 SWOT Analysis & Strategic Conclusions

8.8 Insulet Corporation

8.8.1 Company Profile
8.8.2 Company Snapshot
8.8.3 Strategic Moves and Developments

8.8.3.1 Principal Strategies

8.8.4 SWOT Analysis & Strategic Conclusions

 

LIST OF TABLES

TABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (AS OF MARCH 2013)
TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (AS OF MARCH 2013)
TABLE 3 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY PRODUCT CATEGORY, 2011-2020, ($MILLION)
TABLE 4 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 5 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 6 GLOBAL CGM INSULIN PUMP MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 7 GLOBAL CGM MARKET BY APPLICATION SEGMENTS, 2011 - 2020, ($MILLION)
TABLE 8 GLOBAL CGM MARKET IN DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
TABLE 9 GLOBAL CGM MARKET IN HOSPITALS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
TABLE 10 GLOBAL CGM MARKET IN HOME SETTINGS, BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 11 GLOBAL CGM MARKET BY AGE, 2011 - 2020, ($MILLION)
TABLE 12 TYPE-1 DIABETES (0-14 YEARS), 2013
TABLE 13 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2013 AND 2020
TABLE 14 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 15 THE PREVALENCE OF DIABETES IN THE ADULT POPULATION ACROSS THE U.K. IN 2011
TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
TABLE 17 PREVALENCE ESTIMATES OF DIABETES, 2013 & 2035
TABLE 18 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, AFRICA REGION
TABLE 19 MEDTRONIC BUSINESS SNAPSHOT
TABLE 20 DEXCOM INC. BUSINESS SNAPSHOT
TABLE 21 NOVA NORDISK BUSINESS SNAPSHOT
TABLE 22 SPRING HEALTH SOLUTION LTD BUSINESS SNAPSHOT
TABLE 23 ROCHE BUSINESS SNAPSHOT
TABLE 24 ANIMAS CORPORATION BUSINESS SNAPSHOT
TABLE 25 YPSOMED AG BUSINESS SNAPSHOT
TABLE 26 INSULET CORPORATION BUSINESS SNAPSHOT


LIST OF FIGURES

FIG. 1 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, BY GEOGRAPHY ($BILLION)
FIG. 2 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, 20-79 YEARS ($BILLION)
FIG. 3 TREATMENT OF DIABETES, 2011
FIG. 4 SIMILARITIES IN CAUSE OF PRE-DIABETES AND TYPE-2 DIABETES
FIG. 5 CGM ADOPTION BY DIFFERENT TYPES OF DIABETES PATIENTS
FIG. 6 PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY, (THOUSAND)
FIG. 7 GLOBAL PREVALENCE OF TYPE-2 DIABETES IN 2000 & ESTIMATED PREVALENCE IN 2030
FIG. 8 TOP FACTORS IMPACTING CGM MARKET, 2013-2020
FIG. 9 TOP WINNING STRATEGY IN CGM MARKET, 2010 TO 2013 (SEPTEMBER)
FIG. 10 TOP WINNING STRATEGY IN CGM MARKET BY YEAR
FIG. 11 GLOBAL MARKET PLAYERS POSITIONING
FIG. 12 TOP INVESTMENT POCKETS IN CGM DEVICE MARKETS
FIG. 13 TOP INVESTMENT POCKETS IN CGM APPLICATION MARKETS
FIG. 14 TOP INVESTMENT POCKETS IN CGM GEOGRAPHY MARKETS
FIG. 15 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
FIG. 16 GDP PER CAPITA IN EMERGING ECONOMIES
FIG. 17 EMERGING MARKET CAPITALIZATION STRATEGIES
FIG. 18 GLOBAL CGM MARKET AMONG CHILDREN, 2011-2020, ($MILLION)
FIG. 19 GLOBAL CGM MARKET AMONG TEENS, 2011-2020, ($MILLION)
FIG. 20 GLOBAL CGM MARKET AMONG YOUTH, 2011-2020, ($MILLION)
FIG. 21 GLOBAL CGM MARKET AMONG MIDDLE ELDERLY, 2011-2020, ($MILLION)
FIG. 22 GLOBAL CGM MARKET AMONG AGED, 2011-2020, ($MILLION)
FIG. 23 NORTH AMERICA CGM MARKET, 2013-2020, ($MILLION)
FIG. 24 CASES OF DIABETES BY AGES IN NAC (1000S) (2013 E)
FIG. 25 EUROPE CGM MARKET, 2013-2020, ($MILLION)
FIG. 26 CASES OF DIABETES BY AGES IN EUROPE (1000S) (2013 E)
FIG. 27 ASIA PACIFIC CGM MARKET, 2013-2020, ($MILLION)
FIG. 28 TOP 10 COUNTRIES WITH DIABETES INCIDENCES 2013 AND 2035
FIG. 29 ROW CGM MARKET, 2013-2020, ($MILLION)
FIG. 30 FINANCIAL REVENUES BY BUSINESS UNITS (2013)
FIG. 31 FINANCIAL REVENUES BY GEOGRAPHY (2013)
FIG. 32 FINANCIAL REVENUES BY GEOGRAPHY (2012)

PURCHASE OPTIONS
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT